KRAS mutational status of endoscopic biopsies matches resection specimens
QH Yang, J Schmidt, G Soucy, R Odze… - Journal of clinical …, 2012 - jcp.bmj.com
Aims This study was performed to determine systematically whether KRAS mutational
analysis in biopsy tissue is a reliable indicator of KRAS status in subsequent corresponding …
analysis in biopsy tissue is a reliable indicator of KRAS status in subsequent corresponding …
[PDF][PDF] KRAS and BRAF Mutation Spectrum In 1,035 FFPE Tumor Samples Submitted For Clinical Testing
RPBMJ McGinniss, LD Jamanila, CKRP Bender… - Skin - carislifesciences.com
Results Conclusions ABI3730 and Mutation Surveyor software, mutations were scored as
positive when evident in both the forward and reverse reactions. A total of the 1,035 clinical …
positive when evident in both the forward and reverse reactions. A total of the 1,035 clinical …
KRAS and BRAF mutation spectrum in 1,035 FFPE tumor samples submitted for clinical testing
RP Bender, MJ McGinniss, L Dejesa-Jamanila… - Cancer Research, 2010 - AACR
Activating mutations in both the KRAS and BRAF genes are associated with poor prognosis
and non-response to anti-EGFR therapies in patients with advanced cancers. Clinical …
and non-response to anti-EGFR therapies in patients with advanced cancers. Clinical …